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ARYL SULFONYL FLUORIDE INHIBITORS OF 
ELASTASE AND CHYMOTRYPSIN-LIKE 
ENZY'MES 
fluorides are not usually considered to be highly spe-
cific and in fact phenylmethanesulfonyl fluoride is usu-
ally considered to be a fairly general inhibitOr of serine 
proteases. Lively and Powers showed that the specific-
This is a divisional of co-pending application Ser. No. 
493,064 filed on May 9, 1983, now U.S. Pat. No. 
4,659,855, issued Apr. 21, 1987. 
BACKGROUND OF THE INVENTION 
5 ity of sulfonyl fluorides toward elastase, cathepsin G 
and chymotrypsin could be improved with structural 
changes in the inhibitor (cf. Biochim. Biophys. Acta 
525, pp 171-179(1978)). While a difference in rate of 
26,000 fold was observed between the fastest and slow-
10 est inhibitor, the absolute reactivities of the inhibitors 
were comparatively slow. It is an object of this inven-
tion to find a novel group of aryl sulfonyl fluorides 
which will rapidly and selectively inhibit elastase-like 
and chymotrypsin-like enzymes. 
Selective and reactive protease inhibitors are widely 
used in biomedical research. They are used to identify 
the nature of new proteolytic enzymes encountered in 
isolation and characterization studies. They are also 
used both in research and industrially to prevent unde- 15 
sired proteolysis of proteins and peptides during the 
production, isolation, purification, transport and stor-
age of these valuable materials. They could also be used 
industrially to increase the yields of proteins and pep-
tides produced by cloning or fermentation by inhibiting 20 
proteolysis of the products due to proteases released by 
the parent organism or by contaminating organisms in 
the growth medium. Protease inhibitors could also be 
used to protect proteins and peptides during storage or 
use from proteolysis which would destroy or alter the 25 
activity and/or function of the peptides or proteins. 
DETAILED DESCRIPTION OF THE 
INVENTION 
Certain aryl sulfonyl fluorides have been found to 
selectively inhibit elastase by blocking the active site of 
the enzyme by sulfonylation of the enzyme's active site 
serine residue. The inhibition reaction occurs very rap-
idly. The novel aryl sulfonyl fluoride elastase inhibitors 
have the following structural formula: 
Such uses would include their addition to antibodies, wherein 
enzymes, plasma proteins or other proteins which are X is selected from the group consisting of NH, 0, S, 
widely sold for use in clinical analysis, biomedical re- CH2, and CF2 (but not larger groups such as 
search, therapy, and for many other reasons. 30 NCH3, nor groups such as NS02CF3 which have 
Serine proteases are the most widely distributed class more than 2 atoms other than hydrogen or fluo-
of proteolytic enzymes. Serine proteases can be further rines). 
divided into three main classes based on their substrate Y is selected from the group consisting of CO, S, SO, 
specificity: chymotrypsin-like, elastase-like, and tryp- 0, CF2, NH, and CH2 (but not larger groups such 
sin-like. In addition, there are a few other serine pro- 35 as S02 or -C(OCH3)= which contain 3 or more 
teases which do not fit into any of the above three atoms other than hydrogen or a halide). 
groups. This invention relates only to chymotrypsin- R1 is a C1-s fluoroalkyl (such as CF3, CF2CF3, or 
like and elastase-like enzymes. Chymotrypsin and CF2CF2CF3, but not longer or more bulky groups 
chymotrypsin-like enzymes normally cleave peptide such as CF3CO-Ala, CF3(CF2)6, 
bonds in proteins and peptides where the amino acid 40 CF3CONH(CH2)s, or C6Fs). 
residue on the carbonyl side of the split bond (Pt resi- The R 1 group must be a per fluoroalkyl and not an 
due) is typically Trp, Tyr, Phe, Met, Leu or other alkyl group, and could be branched. Substitution of a 
amino acid residues which contain aromatic or large few of the fluorine atoms in the per fluoroalkyl group 
alkyl side chains. Elastase and elastase-like enzymes, on for hydrogens or other halides will not significantly 
the other hand, cleave peptide bonds where the p 1 45 alter the capacity of the sulfonyl fluoride to inhibit 
amino acid residue is much smaller, typically Ala, Val, elastase. One or two of the carbons in the per fluoroal-
Ser, Leu and other similar amino acids. All of the above kyl group could be replaced by 0, S, NH, or CH2 as 
enzymes have extensive secondary specificity and rec- long as the R 1 group maintains its fluorocarbon and 
ognize amino acid residues removed from the p 1 resi- hydrophobic character. When R 1 is a C4-s per fluoroal-
due. Chymotrypsin-like and elastase-like enzymes are 50 kyl, the sulfonyl fluoride is also an inhibitor of chymo-
widely distributed. They are found in leukocytes (white trypsin-like enzymes. 
blood cells), mast cells, pancreatic juice, and many The substituents on the aromatic ring must be ortho 
other cell types and fluids in higher organisms. They are to each other and not meta or para. The aromatic ring 
also secreted by many types of bacteria, yeast, viruses could be replaced by heterocyclic rings such as a pyri-
and parasites. These enzymes can be very destructive if 55 dine ring or a thiadiazole ring. The -C6l4- could be 
not properly controlled. Thus there is a need for selec- replaced by a cis double bond or substituted double 
tive and reactive inhibitors for these enzymes. bond such as -CH=CH-, -CMe=CH-, -C-
Sulfonyl fluorides have been widely used as inhibitors Me=CMe- (Me=methyl), or -CCF3=CCF3-. 
of serine proteases since their intial discovery by Fahr- The following novel compounds are representative 
ney and Gold (cf. J. Am. Chem. Soc. 85 , pp. 997-1000 60 of the invention: 
(1963)). These reagents, which are fairly stable in aque-
ous solution, inhibit serine proteases by sulfonylation of 
the active site serine residue to give a stable sulfonyl 
enzyme derivative. Sulfonyl fluorides have been shown 
to inhibit most serine proteases including chymotrypsin 65 
(cf. Baker and Hurlbut, J. Med. Chem., 12, pp 118-122 
(1969)), trypsin, elastase, and complement, coagulation, 
and fibrinolytic serine proteases. However, sulfonyl 
3 
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Another novel aryl sulfonyl fluoride elastase inhibitor 
of this invention has the following structural formula: 
3-(C61fs-R 1)-C6li4-S02F 
To use the above identified inhibitors, they are dis-
solved in an organic solvent such as dimethylsulfoxide 
or ethanol and are added to an aqueous solution con-
wherein R2 is a linear group of 0.9 to 2.0 nm bridging 
the two aromatic rings. The R2 group is composed of 6 
to 13 small uncharged atomic groupings such as NH, 
CO, CH2, S02, 0, NH, S and CF2. Ideal inhibitors are 
formed when R 2 has 8 or 11 atomic groupings. Suitable 
R2 groups are 
s taining the protease which is to be inhibited such that 
the final concentration of organic solvent is 25% or less. 
The inhibitors may also be added as solids or in suspen-
sion. The final concentration of the inhibitor in the 
inhibition solution should be at least equal to that of the 
10 protease or proteases in the solution. However, more 
complete and faster inhibition will be obtained if an 
inhibitor concentration of 10 to 1000 fold higher than 
the protease(s) concentration is used The time required 
for complete inhibition will be dependent on the con-
-CH2-0-CO-NH-(CH2)2-CO-NH-
and 
-CH2-0-CO-NH-(CH2)5-CO-NH-. 
15 centration of inhibitor used, but can be calculated from 
the measured rates of inhibition (cf. Yoshimura, Barker, 
and Powers, J. Biol. Chem., 257, pp 5077-5084 (1982)). 
The substituents on the aromatic ring must be meta to 
each other and not ortho or para. Both aromatic rings 20 
could contain substituents such as F, OMe, or N02. 
Both aromatic rings could be replaced by heterocyclic 
rings such as pyridine or thiadiazole rings. 
The following novel compounds are representative 
of the invention: 25 
3-C61f5CH20CONH(CH2)2CONH-C6-
J4-S02F 
The following examples are given to illustrate the 
invention and are not intended to limit it in any manner. 
EXAMPLE 1 
Preparation of 2-(CF3CF2CONH)-C6H4-S02F 
Pentafluoropropionic anhydride (2 ml) was added to 
1 g of 2-NH2-C6li4-S02F. The mixture was stirred 
for 10 min after completion of the exothermic reaction 
and then poured into ice water. The precipitate was 
filtered and recrystallized from methanol-water yield-
ing 0.93 g of a white solid with mp 70 deg centigrade. 3-C61f5CH20CONH(CH2)5CONH-C6-
f4-S02F 30 Anal. Calcd. for C9HsF6N03S: C, 33.66; H, 1.57; N, 
4.36; S, 9.98. Found: C, 33.72, H, 1.62; N, 4.46; S, 9.94. 
Certain aryl sulfonyl fluorides have been found to 
selectively inhibit chymotrypsin-like enzymes such as 
bovine chymotrypsin, human cathepsin G, human skin 
chymase, rat mast cell chymase I and rat mast cell chy- 35 
mase II. The novel aryl sulfonyl fluorides of this inven-
tion have the following structural formula: 
40 
wherein R3 is a linear spacing group of 0.45 to 1.7 nm 
bridging the two aromatic rings. The R3 group is com-
posed of 3 to 11 small uncharged atomic groupings such 
as NH, CO, CH2, CF2, S02, 0, NH, and S. Suitable 
spacing groups are -CH20CONH(CH2)nCONH- 45 
with n= 1, 2 or 5. If n=2 or 5 the inhibitor is very 
selective toward human skin chymase. Another suitable 
spacing group is CONHCH2CONH. Another suitable 
spacing grouping is -CH2NHCONH- and the inhibi-
tor is very selective toward mast cell chymase. 50 The substituents on the second aromatic ring must be 
ortho to each other and not meta or para. Both aromatic 
rings could contain substituents such as F, OMe, or 
N02. Both aromatic rings could be replaced by hetero-
cyclic rings such as pyridine or thiadiazole. 55 The following novel compounds are representative 
of the invention: 
2-C61f5CH20-CO-NH(CH2)CONH-C6-
ff4-S02F 
EXAMPLE2 
Preparation of 
2-(C6HsCH20-CO-NHCH2CONH)-C6. 
li4-S02F 
To a stirred solution of 1.6 g of 2-NH2-C6-
H4-S02F in 40 ml of pyridine cooled to -20 deg centi-
grade was added dropwise 0.40 ml of PCIJ. The solution 
was stirred for 45 min at - 20 and then warmed to room 
temperature. C6HsCH20CONHCH2C02H (1.9 g) was 
added and the reaction refluxed for 3 hrs. The product 
was purified on a silica gel column by elution with 3% 
ethyl acetate-benzene. The oily product was triturated 
with ether yielding 0.745 g of a white solid with mp 
110-112. Anal. Calcd. for C16H1sFN20sS: C, 52.46;, H, 
4.098; N, 7.65. Found: C, 52.72; H, 4.14; N, 7.59. 
Other illustrative examples are incorporated by refer-
ence herein in the Yoshimura, Barker and Powers publi-
cation (cf. J. Biol .. Chem. 257 , pp 5077-5084(1982)). 
The applicant was the director of the research coau-
thored by others. 
What is claimed is: 
1. A process for the inhibition of elastase, serine pro-
teases with elastase-like specificity, chymotrypsin, 
human cathepsin G, human skin chymase, rat mast cell 
protease I and II, bacterial subtilisin, and other serine 
proteases of similar substrate specificity comprising the 
2-C6HsCH20-CO-NH(CH2)2-CONH-C6-
f4-S02F 
60 step of adding to a medium containing the protease an 
effective amount of an inhibitor having the following 
structure: 
2-C6HsCH20-CO-NH(CH2)s-CONH-C6. 
f4-S02F 
2-C61f5CONHCH2CONH-C6H4-S02F 
2-C6HsCH2NHCONH-C6H4-S02F 
65 
wherein 
X is selected from the group consisting of NH, 0, S, 
CH2, and CF2, 
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Y is selected from the group consisting of CO, S, SO, 
0, CF2, NH, and CH2, and 
RI is selected from the group consisting of a C1-s 
perfluoroalkyl. 
2. A process for the inhibition of elastase and other 
serine proteases with elastase like specificity comprising 
the step of adding to a medium containing the protease 
uncharged atomic groupings selected from the group 
consisting of CO, CH2, 0, NH, S and CF2. 
3. A process for the inhibition of chymotrypsin, 
human cathepsin G, human skin chymase, rat mast cell 
5 protease I and II, bacterial subtilisin, and other serine 
proteases of similar substrate specificity comprising the 
step of adding to a medium containing the protease an 
effective amount of an inhibitor having the following 
structure: 
an effective amount of an inhibitor having the following 10 
structure: 
15 
wherein R2 is a linear group of 0.9 to 2.0 run bridging 
the two aromatic rings and is composed of 6 to 13 small 
20 
25 
30 
35 
40 
45 
50 
55 
60 
65 
2-(C6ffs-R3)-C61I4-S02F 
wherein R3 is a linear spacing group of 0.45 to 1.7 run 
bridging the two aromatic rings and is composed of 3 to 
11 small uncharged atomic groupings selected from the 
group consisting of CO, CH2, CF2, S02, 0, NH, and S. 
* * * * * 
